PROshot: DCIS Boost, Radiation Alone for Nasopharyngeal Carcinoma, Prostate SBRT, Sarcoma Lung Metastases, Merkel Cell Carcinoma Abscopal Effect, and Response-Adapted Breast Cancer Radiation
Practical Radiation Oncology · 2023
DOI: 10.1016/j.prro.2022.10.006 ↗Kurz gefasst
Editorial in der Zeitschrift Practical Radiation Oncology, 2023. Verfasst von Caleb Dulaney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Anderson Regional Health System, Meridian, Mississippi. Electronic address: QuadShotNews@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Merkel Cell, Radiosurgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Anderson Regional Health System, Meridian, Mississippi. Electronic address: QuadShotNews@gmail.com.
- Department of Radiation Oncology, Ascension St. Vincent's East, Birmingham, Alabama.
Zitieren
APA
Dulaney, C., & Dover, L. (2023). PROshot: DCIS Boost, Radiation Alone for Nasopharyngeal Carcinoma, Prostate SBRT, Sarcoma Lung Metastases, Merkel Cell Carcinoma Abscopal Effect, and Response-Adapted Breast Cancer Radiation. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2022.10.006
Vancouver
Dulaney C, Dover L. PROshot: DCIS Boost, Radiation Alone for Nasopharyngeal Carcinoma, Prostate SBRT, Sarcoma Lung Metastases, Merkel Cell Carcinoma Abscopal Effect, and Response-Adapted Breast Cancer Radiation. Practical Radiation Oncology. 2023. doi:10.1016/j.prro.2022.10.006
BibTeX
@article{Dulaney2023,
author = {Dulaney, Caleb and Dover, Laura},
title = {PROshot: DCIS Boost, Radiation Alone for Nasopharyngeal Carcinoma, Prostate SBRT, Sarcoma Lung Metastases, Merkel Cell Carcinoma Abscopal Effect, and Response-Adapted Breast Cancer Radiation},
journal = {Practical Radiation Oncology},
year = {2023},
doi = {10.1016/j.prro.2022.10.006}
}
EUVIMED